AI: DeepSeek (deepseek-chat)

Q: {
  "prompt": "Original Transcript:\nDictation: Clinical Interaction – Twin Pregnancy with Obstetric Cholestasis\n Patient Details:\nName: [Fictional Name] Sarah Ahmed\n\n\nAge: 32\n\n\nBMI: 24.7 (weight 68 kg, height 1.66 m)\n\n\nGravida: 2, Para: 1 (previous spontaneous vaginal delivery at term)\n\n\nCurrent Gestation: 32+2 weeks (DCDA twins confirmed on early scan)\n\n\nBooking bloods and anomaly scans: Unremarkable\n\n\nHistory of Presenting Complaint:\n Ms. Ahmed presents with a 10-day history of worsening pruritus, predominantly affecting her palms and soles, with associated sleep disturbance. She denies any new skin rashes or recent medication changes. No history of abdominal pain, dark urine, or pale stools. Fetal movements are reported as normal for both twins. No vaginal bleeding or uterine tightenings.\nRelevant Obstetric History:\nPrevious pregnancy uncomplicated; term vaginal delivery.\n\n\nNo history of intrahepatic cholestasis in prior pregnancy.\n\n\nNo history of preterm labour or hypertensive disorders.\n\n\nRelevant Medical History:\nMild childhood asthma (not on regular treatment).\n\n\nNo known liver or gallbladder disease.\n\n\nMedications & Allergies:\nCurrently taking ferrous fumarate and pregnancy multivitamin.\n\n\nNo known drug allergies.\n\n\nSocial History:\nLives with husband and toddler son.\n\n\nNon-smoker; does not consume alcohol.\n\n\nWorks part-time as a dental nurse; currently on maternity leave.\n\n\nExamination Findings:\nGeneral: Alert and well, no jaundice noted.\n\n\nAbdomen: Uterus consistent with gestational age; fundal height 33 cm.\n\n\nTwins in cephalic/cephalic lie; both heartbeats auscultated and regular.\n\n\nNo uterine tenderness or signs of labour.\n\n\nNo peripheral oedema; BP 118/74 mmHg.\n\n\nNotable Omissions (for testing purposes):\nNo documented baseline bile acid levels from booking bloods.\n\n\nNo record of fetal growth scan within the last 2 weeks.\n\n\nNo documentation of CTG to assess current fetal wellbeing.\n\n\nImpression:\n Twin pregnancy (DCDA) complicated by suspected obstetric cholestasis. Pruritus in the absence of rash raises concern for intrahepatic cholestasis of pregnancy (ICP), particularly given gestation and multifetal pregnancy.\nManagement Plan:\nInvestigations:\n\n\nSerum bile acids and liver function tests (LFTs) urgently.\n\n\nFasting bile acids if initial results are borderline.\n\n\nFull blood count and clotting screen (due to potential risk of coagulopathy).\n\n\nCTG to assess fetal wellbeing.\n\n\nGrowth scan and umbilical artery Dopplers if not done in past 2 weeks.\n\n\nMedical Management:\n\n\nStart ursodeoxycholic acid 500 mg BID while awaiting results.\n\n\nConsider chlorphenamine for symptomatic relief of itching.\n\n\nOngoing Care and Delivery Planning:\n\n\nWeekly bile acids and LFTs.\n\n\nIncrease surveillance: twice-weekly CTGs and weekly growth scans.\n\n\nAim for delivery at 36–37 weeks if bile acids <100 µmol/L.\n\n\nConsider earlier delivery if bile acids ≥100 µmol/L or evidence of fetal compromise.\n\n\nCounseling Provided:\n\n\nDiscussed nature of obstetric cholestasis and increased risk of stillbirth in twin pregnancies.\n\n\nReassured about ongoing monitoring and early delivery plan.\n\n\nAdvised to monitor fetal movements closely and report any reduction.\n\n\nProvided written information and contact details for triage if symptoms worsen.\n\n\nDictated by: Dr. [Fictional Name] Patel\n Date: [Fictional Date]\n--Note: This is a fictional dictation for testing purposes only. No real patient data or medical advice is contained herein.\n\n\n\nGuideline Analysis:\n## Analysis Against Guidelines\n\n### Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\n\nHere is the analysis of the clinical note against the provided guideline, with recommendations for improvement:\n\n### Very Important Recommendations\n1. **Different management plan** - Avoid routine use of ursodeoxycholic acid (UDCA) unless for symptomatic relief, as it does not improve perinatal outcomes.  \n   Reason: The guideline states, \"No treatments improve pregnancy outcomes or reduce bile acid concentrations\" and specifically advises against routine UDCA for adverse perinatal outcomes (bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf).  \n\n2. **Different management plan** - Reconsider the planned delivery timing based on peak bile acid levels (earlier delivery only if ≥100 µmol/L).  \n   Reason: The guideline emphasizes that the risk of stillbirth increases significantly only when bile acids are ≥100 µmol/L, and earlier delivery should be reserved for such cases (bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf).  \n\n3. **Improved patient advice** - Clarify that CTG and ultrasound do not predict or prevent stillbirth in ICP; instead, emphasize monitoring fetal movements.  \n   Reason: The guideline explicitly states, \"Fetal ultrasound and cardiotocography do not predict or prevent stillbirth in ICP, so monitoring fetal movements is advised\" (bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf).  \n\n### Somewhat Important Recommendations\n1. **Additional information needed** - Document baseline bile acid levels from booking bloods to establish a reference for comparison.  \n   Reason: The guideline recommends baseline measurements in subsequent pregnancies to establish normal levels (bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf).  \n\n2. **Improved patient advice** - Discuss the small increased risk of pre-eclampsia and gestational diabetes with ICP and the need for monitoring.  \n   Reason: The guideline notes that women with ICP have a higher chance of developing these conditions and should be monitored (bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf).  \n\n3. **Different management plan** - Avoid routine growth scans and Dopplers unless clinically indicated, as they do not predict stillbirth in ICP.  \n   Reason: The guideline states that additional investigations are not recommended unless itch is severe or comorbidities are present (bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf).  \n\n### Less Important Recommendations\n1. **Improved patient advice** - Provide information about the increased risk of hepatobiliary and immune-mediated diseases later in life.  \n   Reason: The guideline mentions this as a small increased chance but does not prioritize it in management (bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf).  \n\n2. **Additional information needed** - Consider documenting a plan for postnatal follow-up to confirm resolution of ICP.  \n   Reason: The guideline recommends postnatal confirmation of resolution at least 4 weeks after birth (bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf).  \n\n### Unimportant Recommendations\n1. **Improved patient advice** - Mention the lack of impact of ICP on contraception or hormone replacement therapy choices.  \n   Reason: The guideline notes this but it is not directly relevant to acute management (bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf).  \n\n2. **Additional information needed** - Document a plan for baseline bile acid testing in future pregnancies.  \n   Reason: While the guideline recommends this for subsequent pregnancies, it is not urgent for current care (bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf).  \n\n### Summary of Key Adjustments:\n- **Stop routine UDCA** unless for symptomatic relief.  \n- **Adjust delivery timing** to align with bile acid thresholds (≥100 µmol/L).  \n- **De-emphasize CTG/ultrasound** and focus on fetal movement monitoring.  \n- **Clarify risks** of pre-eclampsia/gestational diabetes.  \n- **Avoid unnecessary investigations** like growth scans unless clinically indicated.  \n\nThese changes would better align the note with the guideline's evidence-based recommendations.\n\n\n## Summary\n\nAnalyzed against the most relevant guideline successfully.\n\n*Note: Found 48 relevant guidelines total, analyzed against the most relevant one.*\n\n\nGuideline: Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\n\nPlease extract actionable suggestions from this analysis and format them as specified.",
  "system_prompt": "You are a medical AI assistant that converts clinical guideline analysis into structured, actionable suggestions. \n\nYour task is to analyze the provided guideline analysis and extract specific, actionable suggestions that can be presented to the user for acceptance, rejection, or modification.\n\nFor each suggestion you identify, return ONLY a valid JSON object with the following structure:\n{\n  \"suggestions\": [\n    {\n      \"id\": \"1\",\n      \"originalText\": \"text from transcript that needs changing\",\n      \"suggestedText\": \"proposed replacement text\",\n      \"context\": \"brief explanation of why this change is suggested\",\n      \"category\": \"addition|modification|deletion|formatting\",\n      \"priority\": \"high|medium|low\",\n      \"guidelineReference\": \"specific guideline section or rule\"\n    }\n  ]\n}\n\nCRITICAL FORMATTING REQUIREMENTS:\n- Return ONLY the JSON object - no markdown code blocks, no explanatory text\n- Do not wrap the JSON in ```json or ``` blocks\n- Start your response directly with { and end with }\n- Use sequential numeric IDs starting from \"1\"\n- Ensure all JSON is properly formatted and valid\n\nImportant guidelines:\n- Only suggest changes that are explicitly supported by the guideline analysis\n- Make suggestions specific and actionable\n- Ensure original text selections are precise and findable in the transcript\n- Keep context explanations concise but informative\n- Prioritize suggestions based on clinical importance\n- If no specific suggestions can be made, return {\"suggestions\": []}",
  "transcript_length": 3421,
  "analysis_length": 4382,
  "guideline_id": "bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf",
  "guideline_title": "Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management"
}

A: {
  "suggestions": [
    {
      "id": "1",
      "originalText": "Start ursodeoxycholic acid 500 mg BID while awaiting results.",
      "suggestedText": "Consider ursodeoxycholic acid only for symptomatic relief if pruritus is severe.",
      "context": "Guideline advises against routine UDCA as it does not improve perinatal outcomes",
      "category": "modification",
      "priority": "high",
      "guidelineReference": "bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf"
    },
    {
      "id": "2",
      "originalText": "Aim for delivery at 36–37 weeks if bile acids <100 µmol/L.",
      "suggestedText": "Reserve earlier delivery only for cases with bile acids ≥100 µmol/L.",
      "context": "Risk of stillbirth increases significantly only when bile acids ≥100 µmol/L",
      "category": "modification",
      "priority": "high",
      "guidelineReference": "bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf"
    },
    {
      "id": "3",
      "originalText": "Increase surveillance: twice-weekly CTGs and weekly growth scans.",
      "suggestedText": "Focus on fetal movement monitoring rather than routine CTGs/growth scans.",
      "context": "CTG and ultrasound do not predict or prevent stillbirth in ICP",
      "category": "modification",
      "priority": "high",
      "guidelineReference": "bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf"
    },
    {
      "id": "4",
      "originalText": "Counseling Provided: Discussed nature of obstetric cholestasis and increased risk of stillbirth in twin pregnancies.",
      "suggestedText": "Counseling Provided: Discussed nature of obstetric cholestasis, emphasized fetal movement monitoring, and mentioned small increased risks of pre-eclampsia/gestational diabetes.",
      "context": "Need to clarify monitoring approach and additional risks",
      "category": "modification",
      "priority": "medium",
      "guidelineReference": "bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf"
    },
    {
      "id": "5",
      "originalText": "Growth scan and umbilical artery Dopplers if not done in past 2 weeks.",
      "suggestedText": "Growth scan and umbilical artery Dopplers only if clinically indicated (e.g., severe symptoms or comorbidities).",
      "context": "Avoid routine growth scans/Dopplers unless clinically indicated",
      "category": "modification",
      "priority": "medium",
      "guidelineReference": "bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf"
    },
    {
      "id": "6",
      "originalText": "No documented baseline bile acid levels from booking bloods.",
      "suggestedText": "Document baseline bile acid levels from booking bloods if available.",
      "context": "Baseline measurements help establish reference levels",
      "category": "addition",
      "priority": "medium",
      "guidelineReference": "bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf"
    },
    {
      "id": "7",
      "originalText": "Impression: Twin pregnancy (DCDA) complicated by suspected obstetric cholestasis.",
      "suggestedText": "Impression: Twin pregnancy (DCDA) complicated by suspected obstetric cholestasis. Plan postnatal follow-up to confirm resolution.",
      "context": "Guideline recommends postnatal confirmation of resolution",
      "category": "addition",
      "priority": "low",
      "guidelineReference": "bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf"
    }
  ]
}

--- Token Usage Report ---
Prompt tokens: 2017
Completion tokens: 862
Total tokens: 2879
Estimated cost: $0.001440